ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinicalstage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,700,000 shares of the Company's common stock (or common stock equivalents) at a price of $5.00 per share in a registered direct offering priced above-the-market ...

Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held August 21-22, 2024. This live, interactive online event will give e ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer Conference Call Participants Robert LeBoyer - Noble Capital Markets Jason Kolbert - EF Hutton Jeff Kraws - Crystal Research Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2024 Corporate Update Call. My name is Alex a ...

Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Inv ...

Exhibit 99.1 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024 Ged ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware 87-0455038 (State or other jurisdiction (IRS Employer ...

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinicalstage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. "We are pleased to announce the plans for this novel, exp ...

ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. The primary goal of the planned Phase 2 trial will be to establish efficacy of neoadjuvant Gedeptin therapy combined with an immune checkpoint inhibitor in first-recurrenc ...

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinicalstage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following a clinical advisory committee review. GeoVax and a specially convened clinical advisory committ ...

Compelling Relevance Is Moving GOVX Stock Although Covid-19 fears have been fading since late 2021 and early 2022, the virus remains a major concern. According to the Centers for Disease Control and Prevention (CDC), addressing Covid "remains a public health priority." According to a press release, the company previously disclosed that it was a recipient of an award via the Rapid Response Partnership Vehicle (RRPV) for the development of its GEO-CM04S1 Covid vaccine. The Biomedical Advanced Research and Dev ...